Agenus Inc Asset Resilience Ratio
Agenus Inc asset resilience ratio. Agenus Inc (AGEN) has an Asset Resilience Ratio of 0.73% as of June 2024. The Asset Resilience Ratio measures the percentage of a company's total assets that are held in liquid form (cash and short-term investments). This metric indicates how well-positioned the company is to handle unexpected financial challenges, economic downturns, or strategic opportunities without requiring external financing. See AGEN cash and liquid assets coverage to measure how many days the company can operate on defensive assets alone.
Liquid Assets
Total Assets
Resilience Assessment
Asset Resilience Ratio of Agenus Inc (2000–2023)
Asset resilience ratio of Agenus Inc from 2000 to 2023. This chart shows how Agenus Inc's Asset Resilience Ratio has changed over time. Read Agenus Inc (AGEN) total liabilities for a breakdown of total debt and financial obligations.
Liquid Assets Composition Over Time
This chart breaks down Agenus Inc's liquid assets into cash & equivalents and short-term investments, showing how the composition has evolved over time. For the complete balance sheet picture, see AGEN asset base.
Current Liquid Assets Breakdown
| Component | Amount | % of Total Assets |
|---|---|---|
| Cash & Equivalents | $0.00 | 0% |
| Short-term Investments | $2.14 Million | 0.73% |
| Total Liquid Assets | $2.14 Million | 0.73% |
Asset Resilience Insights
- Limited Liquidity: Agenus Inc maintains only 0.73% of assets in liquid form.
- This low level may indicate efficient asset utilization but could pose risks during economic downturns.
- The company has significant short-term investments, indicating active treasury management.
Agenus Inc Industry Peers by Asset Resilience Ratio
Compare Agenus Inc's asset resilience ratio with other companies in the same industry.
| Company | Industry | Asset Resilience Ratio |
|---|---|---|
|
Hyloris Developmentsen Sa
BR:HYL |
Biotechnology | 1.36% |
|
Biomarin Pharmaceutical Inc
NASDAQ:BMRN |
Biotechnology | 0.00% |
|
Oruka Therapeutics, Inc.
NASDAQ:ORKA |
Biotechnology | 53.11% |
|
Gempharmatech Co. Ltd. A
SHG:688046 |
Biotechnology | 23.95% |
|
Vor Biopharma Inc
NASDAQ:VOR |
Biotechnology | 74.48% |
|
Inventiva S.A
PA:IVA |
Biotechnology | 52.73% |
|
Sunmax Biotechnology Co Ltd
TWO:4728 |
Biotechnology | 10.53% |
|
Guangdong VTR Bio-Tech Co Ltd
SHE:300381 |
Biotechnology | 4.98% |
Agenus Inc Asset Resilience Ratio by Year (2000–2023)
Agenus Inc asset resilience ratio by year from 2000 to 2023. The table below shows the annual Asset Resilience Ratio data for Agenus Inc.
| Year | Asset Resilience Ratio (%) | Liquid Assets | Total Assets | Change |
|---|---|---|---|---|
| 2023-12-31 | 0.14% | $447.00K | $313.91 Million | -3.41pp |
| 2022-12-31 | 3.55% | $14.68 Million | $413.56 Million | +0.33pp |
| 2021-12-31 | 3.22% | $14.99 Million | $465.96 Million | -- |
| 2020-12-31 | 0.00% | $0.00 | $214.51 Million | -- |
| 2018-12-31 | 0.00% | $0.00 | $136.40 Million | -- |
| 2017-12-31 | 0.00% | $0.00 | $138.40 Million | -- |
| 2016-12-31 | 3.18% | $4.99 Million | $156.99 Million | -11.26pp |
| 2015-12-31 | 14.43% | $34.96 Million | $242.23 Million | -5.03pp |
| 2014-12-31 | 19.47% | $14.51 Million | $74.53 Million | -- |
| 2013-12-31 | 0.00% | $0.00 | $34.84 Million | -- |
| 2012-12-31 | 0.00% | $0.00 | $34.67 Million | -- |
| 2011-12-31 | 0.00% | $0.00 | $19.81 Million | -- |
| 2009-12-31 | 21.80% | $10.00 Million | $45.87 Million | +4.25pp |
| 2008-12-31 | 17.55% | $9.99 Million | $56.95 Million | +8.12pp |
| 2007-12-31 | 9.43% | $4.20 Million | $44.54 Million | -12.33pp |
| 2006-12-31 | 21.76% | $15.88 Million | $72.95 Million | -5.63pp |
| 2005-12-31 | 27.39% | $28.53 Million | $104.15 Million | -25.92pp |
| 2004-12-31 | 53.32% | $70.94 Million | $133.06 Million | +30.28pp |
| 2003-12-31 | 23.03% | $32.27 Million | $140.08 Million | -5.70pp |
| 2002-12-31 | 28.74% | $25.60 Million | $89.06 Million | +26.40pp |
| 2000-12-31 | 2.34% | $3.00 Million | $127.97 Million | -- |
About Agenus Inc
Agenus Inc., a clinical-stage biotechnology company, discovers and develops immunotherapies for cancer and infectious diseases in the United States and internationally. It offers Retrocyte Display, an antibody expression platform for the identification of fully human and humanized monoclonal antibodies; and display technologies. It develops QS-21 Stimulon adjuvant, a saponin-based vaccine adjuvan… Read more